Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Sponsor

Astellas Pharma Global Development, Inc. (Industry)

Overall Status

Approved for marketing

CT.gov ID

NCT03070093

Collaborator

(none)

Locations

Study Details

Study Description

Brief Summary

The purpose of this study is to provide expanded access to ASP2215 for subjects with FLT3-mutated relapsed or refractory AML or FLT3-mutated AML in composite complete remission (CRc) (complete remission [CR], complete remission with incomplete hematologic recovery [CRi], complete remission with incomplete platelet recovery [CRp]) with MRD without access to comparable or alternative therapy.

Condition or Disease	Intervention/Treatment	Phase
Acute Myeloid Leukemia (AML) FMS-like Tyrosine Kinase-3 (FLT3) Mutations	Drug: gilteritinib

Detailed Description

The United States Food and Drug Administration (FDA), the Japanese Ministry of Health, Labour and Welfare (MHLW) and Health Canada have approved ASP2215/Gilteritinib (XOSPATA®) for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation.

This treatment protocol is being conducted while phase 3 ASP2215 studies are ongoing in FLT3-mutated AML subjects.

Subjects will complete visits on cycle 1 - days 1, 4, 8, 15; cycle 2 - days 1, 15; cycles 3 to 6 - day 1; and day 1 of every 2 cycles thereafter (i.e., cycle 8 day 1, cycle 10 day 1, etc.) until discontinued from the study.

Subjects will be provided with study medication until the investigator determines the subject is no longer receiving clinical benefit.

An end of treatment visit will be performed within 7 days after last dose of investigational product (ASP2215), or prior to initiation of another anticancer therapy, whichever occurs earlier, followed by a 30-day follow-up. [Specific to investigational sites in Japan: Study population does not include subjects with FLT3-mutated AML in CRc (CR, CRi, CRp) with MRD. Hence, efficacy (MRD response rate and duration of response) data will not be collected for subjects enrolled in Japan.]

Study Design

Study Type:

Expanded Access

Official Title:

A Multicenter, Open-label Treatment Protocol of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Inclusion Criteria:

Subject is considered an adult according to local regulation at the time of signing informed consent.
Subject has a diagnosis of primary AML or AML secondary to myelodysplastic syndrome (MDS) or therapy-related AML according to World Health Organization (WHO) classification.
Subject has presence of the FLT3-mutated relapsed or refractory AML or FLT3-mutated AML in CRc (CR, CRi, CRp) with MRD in bone marrow or peripheral blood. [Specific to investigational sites in Japan: FLT3-mutated AML in CRc (CR, CRi, CRp) with MRD subjects will not be included.]
Subject has refractory or relapsed AML (with or without hematopoietic stem cell transplant [HSCT]) or AML in CRc (CR, CRi, CRp) with MRD by flow cytometry or genetic testing for the FLT3 mutation after induction/consolidation regimen or HSCT. [Specific to investigational sites in Japan: FLT3-mutated AML in CRc (CR, CRi, CRp) with MRD subjects will not be included.]
Subject must wait for at least 5 half-lives after stopping therapy with any investigational agent and before starting ASP2215.
Subject must meet the following criteria as indicated on clinical laboratory tests:
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3x institutional upper limit of normal (ULN)
Serum total bilirubin ≤ 2.5 mg/dL, except for subjects with Gilbert's syndrome
Serum potassium and serum magnesium ≥ institutional lower limit of normal (LLN).
Subject is able to tolerate oral administration of study drug.
Subject who has developed overall grades II-IV acute graft-versus-host disease (GVHD) must satisfy the following criteria:
No requirement of > 0.5 mg/kg of prednisone (or equivalent) daily dose within 1 week of enrollment
No escalation of immunosuppression in terms of increase of corticosteroids or addition of new agent/modality in prior 2 weeks (note that increasing calcineurin inhibitors or sirolimus to achieve therapeutic trough levels is allowed)
Female subject must either:
Be of nonchildbearing potential:
Postmenopausal (defined as at least 1 year without any menses) prior to screening, or
Documented surgically sterile (e.g., hysterectomy, bilateral salpingectomy, bilateral oophorectomy) at least 1 month prior to screening.
Or, if of childbearing potential,
Agree not to try to become pregnant during the study and for at least 180 days after the final study drug administration
And have a negative urine pregnancy test at screening
And, if heterosexually active, agree to use consistently 2 forms of effective contraception per locally accepted standards (1 of which must be a barrier method) starting at screening and throughout the study period and for at least 180 days after the final study drug administration.
Female subject must agree not to breastfeed or donate ova starting at screening and throughout the study period, and for at least 180 days after the final study drug administration.
Male subject (even if surgically sterilized) and partners who are women of childbearing potential must agree to practice 2 forms of effective contraception per locally accepted standards

(1 of which must be a barrier method), starting at screening and throughout the study period and for 120 days after the final study drug administration.

Male subject must not donate sperm starting at screening and throughout the study period and for 120 days after the final study drug administration.
Subject agrees not to participate in another interventional study for AML while on treatment.
Subject who has a diagnosis of HIV may be enrolled as long as the disease is under control on antiretroviral therapy. Precautions should be taken to modify highly active antiretroviral therapy (HAART) regimen to minimize drug interactions.
There is no comparable or satisfactory alternative therapy to treat the subject's AML.

Exclusion Criteria:

Subject is eligible to participate in an ongoing clinical study of ASP2215; or has previously participated in a randomized clinical study of ASP2215 with a primary endpoint of overall survival that is not closed for efficacy.
Subject with QTcF > 450 ms at screening based on local reading.
Subject with a known history of Long QT Syndrome at screening.
Subject was diagnosed with acute promyelocytic leukemia (APL).
Subject has BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
Subject has clinically significant coagulation abnormality unless secondary to AML.
Subject has active hepatitis B or C or an active hepatic disorder.
Subject has uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia, or New York Heart Association (NYHA) Class IV heart failure.
Subject requires treatment with concomitant drugs that are strong inducers of CYP3A.
Subject has any condition which makes the subject unsuitable for study participation.
Subject has hypersensitivity to any of the study drug components.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	UCLA	Los Angeles	California	United States	90095
2	Rocky Mountain Cancer Center-M	Aurora	Colorado	United States	80012
3	Memorial Healthcare System	Pembroke Pines	Florida	United States	33028
4	Northside Hospital	Atlanta	Georgia	United States	30342
5	Georgia Cancer Center at Augusta University	Augusta	Georgia	United States	30912
6	Northwestern University Medical Center	Chicago	Illinois	United States	60611
7	University of Chicago	Chicago	Illinois	United States	60637
8	Indiana Blood and Marrow Transplantation at Franciscan Health Indianapolis	Indianapolis	Indiana	United States	45237
9	Norton Cancer Institute	Louisville	Kentucky	United States	40207
10	Tulane University	New Orleans	Louisiana	United States	70112
11	University of Maryland Medical Center	Baltimore	Maryland	United States	21201
12	Johns Hopkins Hospital	Baltimore	Maryland	United States	21287
13	The Sidney Kimmel Comprehensive Cancer Center -Johns Hopkins University	Baltimore	Maryland	United States	21287
14	Massachusetts General Hospital	Boston	Massachusetts	United States	02114
15	Beth Israel Deaconess Medical Center	Boston	Massachusetts	United States	02215
16	Dana Farber Cancer Institute	Boston	Massachusetts	United States	02215
17	West Michigan Regional Cancer Center	Kalamazoo	Michigan	United States	49007
18	Washington University School of Medicine	Saint Louis	Missouri	United States	63110
19	New Mexico Cancer Care Alliance	Albuquerque	New Mexico	United States	87106
20	Roswell Park Cancer Institute	Buffalo	New York	United States	14263
21	Memorial Sloan Kettering	New York	New York	United States	10021
22	Weill Cornell Medical College	New York	New York	United States	10065
23	Duke University Medical Center	Durham	North Carolina	United States	27710
24	Wake Forest Baptist Hospital	Winston-Salem	North Carolina	United States	27157
25	Ohio State University	Columbus	Ohio	United States	43210
26	Providence Portland Medical Center	Portland	Oregon	United States	97213
27	Penn State Hershey Medical Center	Hershey	Pennsylvania	United States	17033
28	Thomas Jefferson University	Philadelphia	Pennsylvania	United States	19066
29	UPCI	Pittsburgh	Pennsylvania	United States	15232
30	Vanderbilt University	Nashville	Tennessee	United States	37232
31	Huntsman Cancer Institute University of Utah	Salt Lake City	Utah	United States	84112
32	WVU Medicine Cancer	Morgantown	West Virginia	United States	26506
33	Site CA15002	Halifax	Nova Scotia	Canada
34	Site CA15003	Toronto	Ontario	Canada
35	Site CA15001	Montreal	Quebec	Canada	H1T 2M4
36	Site CA15005	Vancouver		Canada
37	Site JP81001	Nagoya	Aichi	Japan
38	Site JP81002	Shinagawa-ku	Tokyo	Japan
39	Site JP81003	Fukuoka		Japan